Primary bone cancer is rare and, unlike many other cancers, has no proven lifestyle-based prevention strategy. About 4,110 new cases are expected in the United States in 2026, and most arise without a clear preventable cause. That doesn’t mean you’re powerless. Understanding who faces elevated risk, minimizing known exposures, and catching problems early are the most practical steps available.
Why Bone Cancer Is Hard to Prevent
Most prevention advice for common cancers centers on diet, exercise, tobacco, and alcohol. Primary bone cancers, particularly osteosarcoma and Ewing sarcoma, don’t follow that pattern. They often strike children, teenagers, and young adults during periods of rapid bone growth, and the triggers appear to be largely genetic or related to prior medical treatments rather than daily habits. No specific food, supplement, or exercise routine has been shown in clinical research to reduce the risk of developing a primary bone tumor.
This is fundamentally different from cancers that metastasize (spread) to bone from the breast, prostate, or lung. Those secondary bone cancers are a separate category, and preventing them means addressing the original cancer. The information here focuses on cancers that start in the bone itself.
Know Your Genetic Risk
The clearest risk factors for primary bone cancer are inherited genetic conditions. If any of these run in your family, awareness and surveillance are your best tools.
Li-Fraumeni syndrome is caused by a mutation in the TP53 gene, which normally acts as a powerful brake on tumor growth. People with this mutation face a significantly elevated lifetime risk of several cancers, including osteosarcoma. Recommended screening includes annual whole-body MRI to catch tumors early, including in bone.
Hereditary retinoblastoma involves a mutation in the RB1 gene. Children who survive retinoblastoma (a childhood eye cancer) have an increased risk of developing bone and soft tissue sarcomas later in life, most notably osteosarcoma. Some people with apparently sporadic retinoblastoma actually carry a mosaic version of the RB1 mutation at low levels, which can be detected with genetic testing and has implications for long-term monitoring and family planning.
These syndromes are rare, and identifying them requires a high index of suspicion. If your family has a pattern of unusual or early-onset cancers, genetic counseling can determine whether testing is warranted. Early recognition of a predisposition syndrome allows at-risk family members to be identified and monitored before a tumor ever appears.
Radiation Exposure and Prior Cancer Treatment
Previous radiation therapy is one of the few established environmental causes of bone cancer. The risk depends heavily on dose. Radiation below 2,000 cGy (a unit measuring absorbed dose) carries negligible risk. Above 6,000 cGy, the risk of a secondary bone cancer increases markedly.
The lag time between radiation treatment and the appearance of a bone tumor averages about 16 years in adults. In young children, that latency period is shorter, averaging around 9.6 years. This means someone treated with high-dose radiation for a childhood cancer could develop a bone sarcoma in their teens or twenties.
Modern radiation oncology aims to limit unnecessary exposure to surrounding bone and tissue, using more precisely targeted techniques than were available decades ago. If you or your child received radiation therapy, particularly at high doses to areas near bone, your oncologist may recommend periodic imaging to watch for changes over the years that follow.
Paget’s Disease and Bone Health
Paget’s disease of bone is a chronic condition in which bones break down and rebuild abnormally, becoming enlarged and fragile. A small percentage of people with Paget’s disease develop osteosarcoma in affected bones, making it a recognized risk factor, particularly in older adults.
You might expect that treating Paget’s disease with bisphosphonates (medications that slow bone breakdown) would reduce the chance of cancerous transformation. However, clinical guidelines are clear: there is insufficient evidence to show that bisphosphonates prevent bone cancer in Paget’s disease, and they are not recommended for that purpose. Treatment of Paget’s disease is still valuable for managing pain, preventing fractures, and preserving joint function, but cancer prevention is not a demonstrated benefit.
If you have Paget’s disease, paying attention to new or worsening bone pain, swelling, or a sudden change in a previously stable area is important. These could signal a complication that warrants imaging.
Occupational and Chemical Exposures
A large European case-control study found that certain occupations carried a higher risk of bone sarcoma. Woodworkers had roughly 2.7 times the risk of the general population. Blacksmiths, toolmakers, and machine-tool operators had about twice the risk. Construction workers showed a smaller, borderline elevation.
Pesticide use also stood out. People who had ever used pesticides had approximately 2.3 times the risk of bone sarcoma, with similar increases seen for both insecticides and herbicides. Interestingly, the risk did not climb steadily with longer duration of use, which makes the relationship harder to interpret, but the overall association was statistically significant.
If you work in these fields, standard protective measures matter: wearing appropriate personal protective equipment, following safety protocols for chemical handling, and minimizing unnecessary skin contact or inhalation of industrial substances. These are sensible steps regardless of bone cancer specifically, but the data suggest they may be particularly relevant here.
Early Detection When Prevention Isn’t Possible
Because most bone cancers can’t be prevented through modifiable behavior, early detection becomes the most practical way to improve outcomes. There is no routine screening test for bone cancer in the general population, and given how rare the disease is, mass screening would not be useful. But for people at increased risk due to genetic conditions or prior radiation therapy, doctors may recommend closer monitoring with periodic imaging or physical exams.
For everyone else, recognizing early symptoms is key. The most common warning signs of bone cancer are persistent bone pain that worsens over time, swelling or tenderness near the affected area, and a weakened bone that fractures unexpectedly. Bone pain from cancer often intensifies at night or during activity and doesn’t resolve with rest the way a strain or bruise would. In children and teenagers, bone pain during a growth spurt is common and usually harmless, but pain that is localized to one spot, progressively worsening, or accompanied by visible swelling deserves prompt medical evaluation.
Early-stage bone tumors are far more treatable than advanced ones. A delay of weeks or months in seeking evaluation for persistent, unexplained bone pain can change the range of treatment options available. The rarity of the disease means most bone pain will turn out to be something benign, but that same rarity means it’s easy to dismiss warning signs until the tumor has grown.